首页> 美国卫生研究院文献>The Oncologist >Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China

【2h】

Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China

机译：曲妥珠单抗在资源有限或资源丰富地区的使用差异及其对HER2阳性乳腺癌的生存获益：来自中国的一项现实世界研究

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

Background.Trastuzumab is a key component of therapy for human epidermal growth receptor 2 (HER2) positive breast cancer. Because real‐world data are lacking, the present research was conducted to evaluate the actual use of and the effectiveness of trastuzumab in the real world in China.

机译：背景：曲妥珠单抗是人类表皮生长受体2（HER2）阳性乳腺癌治疗的关键组成部分。由于缺乏现实世界的数据，本研究旨在评估曲妥珠单抗在中国现实世界中的实际使用和有效性。

著录项

期刊名称 The Oncologist
作者
Jianbin Li; Shusen Wang; Yongsheng Wang; Xiaojia Wang; Haibo Wang; Jifeng Feng; Qingyuan Zhang; Tao Sun; Quchang Ouyang; Yongmei Yin; Yinhua Liu; Cuizhi Geng; Min Yan; Zefei Jiang; *;
展开▼
作者单位

展开▼
年(卷),期 2017(22),11
年度 2017
页码 1333–1338
总页数 6
原文格式 PDF
正文语种
中图分类肿瘤学;
关键词
Human epidermal growth receptor 2 positive breast cancer Medical resource disparity Real‐world research Survival;

机译：人类表皮生长受体2阳性乳腺癌;医学资源差异;真实世界研究;生存;

相似文献

外文文献
中文文献
专利

1. Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China [J] . Li Jianbin, Wang Shusen, Wang Yongsheng, The oncologist . 2017,第11期

机译：资源有限或资源丰富地区的曲妥珠单抗使用的差异及其对HER2阳性乳腺癌的生存效益：来自中国的真实研究
2. Disparities of trastuzumab use in resources limited or abundant regions and its survival benefit on HER2 positive breast cancer: a real world research from China [J] . Li J., Zhang H., Wang S., The Breast : . 2017,第期

机译：在资源有限或丰富的地区使用曲妥珠单抗的差异及其对HER2阳性乳腺癌的生存效益：来自中国的真实世界研究
3. Disparities of Trastuzumab Use in Resourcea??Limited or Resourcea??Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Reala??World Study from China [J] . Jianbin Li, Shusen Wang, Yongsheng Wang, The oncologist . 2017,第11期

机译：曲妥珠单抗在资源有限或资源丰富地区的使用差异及其对HER2阳性乳腺癌的生存获益：来自中国的世界研究
4. Elevated WBP2 Expression in HER2-Positive Breast Cancers Correlates with Sensitivity to Trastuzumab-Based Neo-Adjuvant Therapy: A Retrospective and Multicentric Study [C] . Yoon Pin Lim International Molecular Medicine Tri-Conference. . 2019

机译：HER2阳性乳腺癌中的WBP2表达升高与基于曲妥珠单抗的新辅助治疗的敏感性相关：回顾性和多中心研究
5. A phase Ib study of safety and pharmacokinetics of trastuzumab emtansine and pertuzumab in Japanese patients with HER2-positive metastatic breast cancer [D] . NOGUCHI, Emi 2019

机译：Ib期研究曲妥珠单抗氨丹宁和帕妥珠单抗在日本HER2阳性转移性乳腺癌患者中的安全性和药代动力学
6. Overall survival benefit with pertuzumab trastuzumab and docetaxel for HER2-positive metastatic breast cancer in CLEOPATRA a randomised Phase 3 study [O] . Sandra M. Swain, Sung-Bae Kim, Javier Cortés, -1

机译：帕妥珠单抗曲妥珠单抗和多西紫杉醇对CLEOPATRA HER2阳性转移性乳腺癌的总体生存获益一项随机的3期研究
7. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients [O] . Jihong Guo, Qing Li, Pin Zhang, 2019

机译：Trastuzumab加上人表皮生长因子受体2（HER2） - 阳性早期乳腺癌的辅助化学疗法：中国患者的真实回顾性研究
8. Phase II Study of a HER-2/neu (HER2) Intracellular Domain (ICD) Peptide- Based Vaccine Administered to Stage IIIB and IV HER2 Positive Breast Cancer Patients Receiving Trastuzumab Monotherapy; Annual rept. 27 Apr 2007-26 Apr 2008 [R] . Disis, M. L. 2008

机译：对接受曲妥珠单抗单一疗法的IIIB和IV期HER2阳性乳腺癌患者施用HER-2 / neu（HER2）细胞内结构域（ICD）基于肽的疫苗的II期研究;年度报告。 2007年4月27日至2008年4月26日

Disparities of Trastuzumab Use in Resource‐Limited or Resource‐Abundant Regions and Its Survival Benefit on HER2 Positive Breast Cancer: A Real‐World Study from China

摘要

著录项

相似文献

相关主题

期刊订阅